Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500720 · ClinicalTrials.gov registry record · Phase 2
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
NCT01500720 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 179 participants.
The verdict
NCT01500720, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
Study Summary
Primary Objective: To demonstrate progression free survival (PFS) improvement for cabazitaxel compared to topotecan in participants with sensitive or resistant/refractory small cell lung cancer following a first line platinum based chemotherapy. Secondary Objectives: * To assess disease progression free rate at 12 weeks * To assess Response Rate (Response Evaluation Criteria in Solid Tumor \[RECIST\] 1.1) and duration of response * To assess Overall Survival (OS) * To assess the Safety (National Cancer Institute - Common Toxicity Criteria \[NCI-CTC\] version 4.03) * To assess the Health-Related Quality of Life (HRQoL)
Interventions
- DRUG Topotecan
- DRUG Cabazitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01500720
The ClinicalTrials.gov registry entry for NCT01500720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT01500720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01500720 about?
NCT01500720 is a clinical study titled "Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer". Primary Objective: To demonstrate progression free survival (PFS) improvement for cabazitaxel compared to topotecan in participants with sensitive or resistant/refractory small cell lung cancer following a first line platinum based chemotherapy. Secondary Objectives: * To assess disease progressi...
What is the current status of trial NCT01500720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2012-03. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01500720?
The interventions under investigation include: Topotecan (DRUG), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT01500720?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.